Document Detail

Global endometrial ablation devices.
MedLine Citation:
PMID:  18303511     Owner:  NLM     Status:  MEDLINE    
Since 1997, the US Food and Drug Administration has approved 5 global endometrial ablation (GEA) devices for the minimally invasive treatment of idiopathic menorrhagia. These include a variety of modalities to ablate the endometrium, including thermal balloon, circulated hot fluid, cryotherapy, radiofrequency electrosurgery, and microwave energy. Level I evidence is available to support high subjective satisfaction rates regardless of GEA method. There is a wide range of amenorrhea rates (13.9% to 55.3%) among GEA methods. Complication rates associated with GEA procedures are generally low when performed by physicians familiar with these devices, working under standard protocols compared with some of the major complications seen after these devices have been used by a broader range of physicians without study protocols. Adherence to patient selection and protocols is recommended.
Sarah Zarek; Howard T Sharp
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical obstetrics and gynecology     Volume:  51     ISSN:  1532-5520     ISO Abbreviation:  Clin Obstet Gynecol     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-27     Completed Date:  2008-04-04     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0070014     Medline TA:  Clin Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  167-75     Citation Subset:  IM    
Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amenorrhea / surgery*
Balloon Dilatation
Clinical Competence
Endometrium / surgery*
Gynecologic Surgical Procedures / methods*
Hot Temperature
Patient Satisfaction
Treatment Outcome

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Magnetic resonance-guided focused ultrasound surgery.
Next Document:  Botulinum toxin: new option for refractory lower urinary tract symptoms in women.